Ameritas Investment Partners, Inc. Seagen Inc. Transaction History

Ameritas Investment Partners, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $216,023 - $243,828	1,128 Added 27.72%	5,197 $1.1 Million
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $12,759 - $14,025	68 Added 1.7%	4,069 $783,000
Q1 2023 May 10, 2023	BUY	$127.59 - $203.08 $7,017 - $11,169	55 Added 1.39%	4,001 $810,000
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $16,901 - $20,040	-144 Reduced 3.52%	3,946 $507,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $5,410 - $7,204	40 Added 0.99%	4,090 $559,000
Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $5,984 - $9,863	55 Added 1.38%	4,050 $716,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $17,678 - $23,666	124 Added 3.2%	3,995 $618,000
Q2 2021 Aug 06, 2021	BUY	$135.08 - $161.1 $10,131 - $12,082	75 Added 1.98%	3,871 $611,000
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $6,875 - $9,540	50 Added 1.33%	3,796 $527,000
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $616,703 - $793,889	3,746 New	3,746 $656,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.